Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

July 14, 2025

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

CMS Announces Negotiated Medicare Prices for First 10 Drugs

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

News Daily News

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

August 13, 2024

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

August 05, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

June 05, 2023

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

April 19, 2023

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

News Daily News

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

Michael O'Riordan

March 29, 2023

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 05, 2022

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

April 20, 2022

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

FDA Approves Dapagliflozin for CKD Patients

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.